We are live on ! Find out more
PIM

Platinum Investment Management Portfolio holdings

AUM $397M
1-Year Est. Return 63.96%
This Fund
S&P 500
This Quarter Est. Return
+2.88%
1 Year Est. Return
+63.96%
3 Year Est. Return
+135%
5 Year Est. Return
+149.46%
10 Year Est. Return
+636.06%
AUM
$2.56B
AUM Growth
-$317M
Cap. Flow
-$320M
Cap. Flow %
-12.47%
Top 10 Hldgs %
59.29%
Holding
159
New
16
Increased
42
Reduced
55
Closed
15

Top Buys

Rank Stock Value
1
CCJ icon
Cameco
CCJ
+$66.6M
2
PDD icon
Pinduoduo
PDD
+$33.9M
3
MBLY icon
Mobileye
MBLY
+$25.9M
4
VAL icon
Valaris
VAL
+$15.4M
5
CSL icon
Carlisle Companies
CSL
+$10.5M

Top Sells

Rank Stock Value
1
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$63.2M
2
GILD icon
Gilead Sciences
GILD
+$53.6M
3
SU icon
Suncor Energy
SU
+$46.6M
4
RH icon
RH
RH
+$34.8M
5
ZTO icon
ZTO Express
ZTO
+$34.6M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 18.32%
2 Technology 17.4%
3 Industrials 16.93%
4 Energy 15.13%
5 Financials 11.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RYZB
51
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$4.93M 0.19%
+222,222
New +$4.67M
COGT icon
52
Cogent Biosciences
COGT
$7.1B
$4.64M 0.18%
475,837
-1,243
-0.3% -$14.7K
GOSS icon
53
Gossamer Bio
GOSS
$86.1M
$4.46M 0.17%
5,357,778
+2,994,608
+127% +$3.45M
INBX
54
DELISTED
Inhibrx, Inc. Common Stock
INBX
$4.2M 0.16%
229,036
– –
NSTG
55
DELISTED
NanoString Technologies, Inc.
NSTG
$3.93M 0.15%
2,285,137
+1,168,745
+105% +$3.56M
ACIU icon
56
AC Immune
ACIU
$232M
$3.77M 0.15%
1,322,462
– –
RCUS icon
57
Arcus Biosciences
RCUS
$3.66B
$3.67M 0.14%
204,398
-28,214
-12% -$567K
SGMT icon
58
Sagimet Biosciences
SGMT
$591M
$3.38M 0.13%
+383,913
New +$5.11M
MRUS
59
DELISTED
Merus
MRUS
$3.35M 0.13%
142,029
-8,209
-5% -$199K
ALLE icon
60
Allegion
ALLE
$14.1B
$3.28M 0.13%
+31,507
New +$3.55M
ESPR
61
DELISTED
Esperion Therapeutics
ESPR
$3.13M 0.12%
3,189,517
-280,117
-8% -$405K
MTCH icon
62
Match Group
MTCH
$8.43B
$3.12M 0.12%
79,760
-28,066
-26% -$1.24M
IMTX icon
63
Immatics
IMTX
$1.33B
$3.11M 0.12%
268,211
– –
BIO icon
64
Bio-Rad Laboratories Class A
BIO
$9.48B
$3.1M 0.12%
8,636
– –
HCM icon
65
HUTCHMED
HCM
$2.18B
$3.08M 0.12%
182,052
– –
AMZN icon
66
Amazon
AMZN
$3T
$2.87M 0.11%
22,613
+15,315
+210% +$2.05M
VERA icon
67
Vera Therapeutics
VERA
$2.27B
$2.75M 0.11%
200,302
-9,398
-4% -$161K
NFLX icon
68
Netflix
NFLX
$318B
$2.71M 0.11%
71,790
-75,430
-51% -$3.2M
GPCR icon
69
Structure Therapeutics
GPCR
$3.82B
$2.65M 0.1%
52,461
+37,461
+250% +$1.21M
WVE icon
70
Wave Life Sciences
WVE
$1.2B
$2.62M 0.1%
455,331
– –
ARWR icon
71
Arrowhead Research
ARWR
$12.5B
$2.61M 0.1%
97,168
– –
ZYME icon
72
Zymeworks
ZYME
$1.71B
$2.6M 0.1%
409,839
– –
ORCL icon
73
Oracle
ORCL
$435B
$2.56M 0.1%
24,143
+6,021
+33% +$697K
CNTG
74
DELISTED
Centogene N.V. Common Shares
CNTG
$2.52M 0.1%
2,377,150
– –
CVAC
75
DELISTED
CureVac
CVAC
$2.48M 0.1%
363,280
+137,146
+61% +$1.21M
1 2
3
4 5

Similar funds

EH
EMG Holdings Old Greenwich, Connecticut $397M AUM 9.97% 1-Year Est. Return
TPWA
Twin Peaks Wealth Advisors Burlingame, California $397M AUM 23.23% 1-Year Est. Return
VC
Vision Capital Toronto, Ontario, Canada $397M AUM 0.8% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GPC
Greenstone Partners & Co Larkspur, California $395M AUM 35.56% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
HBFP
Henderson Brothers Financial Partners Pittsburgh, Pennsylvania $395M AUM

Platinum Investment Management's Q3 2023 Portfolio in Review

As of Q3 2023, Platinum Investment Management held 159 positions worth $2.56B, down 11% from $2.88B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Platinum Investment Management withdrew a net $320M in Q3 2023, closing 15 positions and reducing 55 holdings. Its most notable exit was Gilead Sciences, an estimated $53.6M position sold in full.

By sector, the portfolio is most concentrated in Consumer Discretionary at 18% of assets, up from 15% a quarter earlier, followed by Technology and Industrials.

Against the trend, Platinum Investment Management opened a new position in Bicycle Therapeutics worth $5.74M.

  • Platinum Investment Management's largest Q3 2023 buy was Bicycle Therapeutics: 285,479 shares worth $5.74M.
  • Platinum Investment Management added most to Cameco in Q3 2023, an estimated $66.6M increase.
  • Platinum Investment Management's biggest Q3 2023 reduction was Alphabet (Google) Class A, cutting an estimated $63.2M.
  • Platinum Investment Management fully exited Gilead Sciences in Q3 2023, selling an estimated $53.6M.
  • Platinum Investment Management's ten largest holdings make up 59% of its $2.56B portfolio in Q3 2023.
  • Platinum Investment Management opened 16 new positions and closed 15 in Q3 2023.
  • Platinum Investment Management's portfolio value fell 11% quarter-over-quarter to $2.56B.

Based on Platinum Investment Management's 13F filing for Q3 2023, filed 3 Nov 2023.